Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Novartis Ag (NVSEF) Short-Term Debt issuances (2017 - 2025)

Historic Short-Term Debt issuances for Novartis Ag (NVSEF) over the last 9 years, with Q4 2025 value amounting to -$837.0 million.

  • Novartis Ag's Short-Term Debt issuances fell 338750.0% to -$837.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.0 million, marking a year-over-year decrease of 9947.81%. This contributed to the annual value of $5.0 million for FY2025, which is 9947.81% down from last year.
  • As of Q4 2025, Novartis Ag's Short-Term Debt issuances stood at -$837.0 million, which was down 338750.0% from -$564.0 million recorded in Q3 2025.
  • Novartis Ag's 5-year Short-Term Debt issuances high stood at $2.3 billion for Q1 2021, and its period low was -$2.4 billion during Q4 2021.
  • Moreover, its 5-year median value for Short-Term Debt issuances was -$221.0 million (2023), whereas its average is -$87.8 million.
  • As far as peak fluctuations go, Novartis Ag's Short-Term Debt issuances skyrocketed by 18025.39% in 2024, and later crashed by 338750.0% in 2025.
  • Novartis Ag's Short-Term Debt issuances (Quarter) stood at -$2.4 billion in 2021, then soared by 49.11% to -$1.2 billion in 2022, then skyrocketed by 156.35% to $674.0 million in 2023, then tumbled by 103.56% to -$24.0 million in 2024, then tumbled by 3387.5% to -$837.0 million in 2025.
  • Its Short-Term Debt issuances was -$837.0 million in Q4 2025, compared to -$564.0 million in Q3 2025 and $850.0 million in Q2 2025.